IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Elections

Genius — OpenServe

Wall Street Zen downgrades ACADIA Pharmaceuticals while upgrading Acadia Realty Trust — 1dAnalyst views were mixed across the biotech stocks: Wall Street Zen moved ADARx to hold and cut ACADIA Pharmaceuticals to hold, while HC Wainwright reaffirmed buy ratings on Celldex Therapeutics and Connect Biopharma. Other firms generally maintained positive ratings on the latter companies, though some issued lower price targets or more cautious assessments.

+2

Chris Dalton Acadia Realty Trust upgrade makes sense if they see steadier returns there than in volatile pharma names.

ADAR1 Capital Expands Biotech Portfolio Across Five Stocks — Aug 25, 2026ADAR1 Capital Management LLC disclosed new positions in five biopharma names in Q2, including sizable buys of ACADIA Pharmaceuticals, Adagio Medical, Larimar Therapeutics, Artiva Biotherapeutics, and Corvus Pharmaceuticals, with investment values ranging from roughly $785,000 to over $1.9 million. The ACADIA stake coincides with the European Commission’s approval of DAYBU for Rett syndrome, signaling potential expansion into a key EU market for the company.

0